

Tenofovir alafenamide fumarate

Catalog No: tcsc3367



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

379270-38-9

Formula:

$C_{25}H_{33}N_6O_9P$

Pathway:

Anti-infection;Anti-infection

Target:

Reverse Transcriptase;HIV

Purity / Grade:

>98%

Solubility:

H2O : ≥ 25 mg/mL (42.19 mM); DMSO : ≥ 36 mg/mL (60.76 mM)

Alternative Names:

GS-7340 (fumarate)

Observed Molecular Weight:

592.54


Product Description

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.

IC50 & Target: HIV-1, NRTIs^[1]

In Vitro: Tenofovir alafenamide antiviral activities are similar across all cell types, ranging from 5 to 7 nM, while the CC₅₀ varies from 4.7 to 42 µM for MT-4 and MT-2 cells, respectively. The antiviral activity of TAF is evaluated against a panel of HIV-1 and HIV-2 isolates, including HIV-1 group M subtypes A to G, as well as group N and O isolates. Overall, for the 29 primary HIV-1 isolates tested in PBMCs, TAF EC₅₀s range from 0.1 to 12 nM, with a mean EC₅₀ of 3.5 nM compared to a mean EC₅₀ of 11.8 nM for AZT, which is used as an internal control. For the HIV-2 isolates, the mean EC₅₀s are 1.8 nM for TAF and 6.4 nM for AZT^[2].

In Vivo: Tenofovir alafenamide hemifumarate is an amidate prodrug of Tenofovir with good oral bioavailability and increases plasma stability compared to Tenofovir disoproxil fumarate (TDF)^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!